FF — Fine Foods & Pharmaceuticals NTM SpA Balance Sheet
0.000.00%
- €217.61m
- €269.24m
- €243.75m
- 69
- 53
- 86
- 84
Annual balance sheet for Fine Foods & Pharmaceuticals NTM SpA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
| 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | ARS | ARS | ARS | ARS | ARS | 
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS | 
| Status: | Final | Final | Final | Final | Final | 
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 75 | 95.1 | 76.7 | 22.8 | 19.2 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 12.7 | 31.9 | 45.1 | 43.9 | 43.2 | 
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 111 | 172 | 165 | 111 | 96.4 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 93.8 | 109 | 109 | 110 | 129 | 
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 207 | 303 | 300 | 242 | 243 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 49.1 | 110 | 84 | 101 | 70.7 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 66.4 | 156 | 167 | 115 | 111 | 
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 141 | 147 | 133 | 127 | 132 | 
| Total Liabilities & Shareholders' Equity | 207 | 303 | 300 | 242 | 243 | 
| Total Common Shares Outstanding |